BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 38727812)

  • 1. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers.
    Hanada KI; Zhao C; Gil-Hoyos R; Gartner JJ; Chow-Parmer C; Lowery FJ; Krishna S; Prickett TD; Kivitz S; Parkhurst MR; Wong N; Rae Z; Kelly MC; Goff SL; Robbins PF; Rosenberg SA; Yang JC
    Cancer Cell; 2022 May; 40(5):479-493.e6. PubMed ID: 35452604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine learning for the identification of neoantigen-reactive CD8 + T cells in gastrointestinal cancer using single-cell sequencing.
    Sun H; Han X; Du Z; Chen G; Guo T; Xie F; Gu W; Shi Z
    Br J Cancer; 2024 Jun; ():. PubMed ID: 38849478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-cell sequencing of tumour infiltrating T cells efficiently identifies tumour-specific T cell receptors based on the T cell activation score.
    Zhang C; Li S; Shen L; Teng X; Xiao Y; Yang W; Lu Z
    Cancer Immunol Immunother; 2024 May; 73(7):123. PubMed ID: 38727812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers.
    Zheng C; Fass JN; Shih YP; Gunderson AJ; Sanjuan Silva N; Huang H; Bernard BM; Rajamanickam V; Slagel J; Bifulco CB; Piening B; Newell PHA; Hansen PD; Tran E
    Cancer Cell; 2022 Apr; 40(4):410-423.e7. PubMed ID: 35413272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers.
    Lowery FJ; Krishna S; Yossef R; Parikh NB; Chatani PD; Zacharakis N; Parkhurst MR; Levin N; Sindiri S; Sachs A; Hitscherich KJ; Yu Z; Vale NR; Lu YC; Zheng Z; Jia L; Gartner JJ; Hill VK; Copeland AR; Nah SK; Masi RV; Gasmi B; Kivitz S; Paria BC; Florentin M; Kim SP; Hanada KI; Li YF; Ngo LT; Ray S; Shindorf ML; Levi ST; Shepherd R; Toy C; Parikh AY; Prickett TD; Kelly MC; Beyer R; Goff SL; Yang JC; Robbins PF; Rosenberg SA
    Science; 2022 Feb; 375(6583):877-884. PubMed ID: 35113651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotype, specificity and avidity of antitumour CD8
    Oliveira G; Stromhaug K; Klaeger S; Kula T; Frederick DT; Le PM; Forman J; Huang T; Li S; Zhang W; Xu Q; Cieri N; Clauser KR; Shukla SA; Neuberg D; Justesen S; MacBeath G; Carr SA; Fritsch EF; Hacohen N; Sade-Feldman M; Livak KJ; Boland GM; Ott PA; Keskin DB; Wu CJ
    Nature; 2021 Aug; 596(7870):119-125. PubMed ID: 34290406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment.
    Pauken KE; Shahid O; Lagattuta KA; Mahuron KM; Luber JM; Lowe MM; Huang L; Delaney C; Long JM; Fung ME; Newcomer K; Tsai KK; Chow M; Guinn S; Kuchroo JR; Burke KP; Schenkel JM; Rosenblum MD; Daud AI; Sharpe AH; Singer M
    J Exp Med; 2021 Apr; 218(4):. PubMed ID: 33651880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers.
    Nagarsheth NB; Norberg SM; Sinkoe AL; Adhikary S; Meyer TJ; Lack JB; Warner AC; Schweitzer C; Doran SL; Korrapati S; Stevanović S; Trimble CL; Kanakry JA; Bagheri MH; Ferraro E; Astrow SH; Bot A; Faquin WC; Stroncek D; Gkitsas N; Highfill S; Hinrichs CS
    Nat Med; 2021 Mar; 27(3):419-425. PubMed ID: 33558725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8
    van der Leun AM; Thommen DS; Schumacher TN
    Nat Rev Cancer; 2020 Apr; 20(4):218-232. PubMed ID: 32024970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma.
    Tan Q; Zhang C; Yang W; Liu Y; Heyilimu P; Feng D; Xing L; Ke Y; Lu Z
    J Immunother Cancer; 2019 Aug; 7(1):232. PubMed ID: 31462302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Integration of Single-Cell Data.
    Stuart T; Butler A; Hoffman P; Hafemeister C; Papalexi E; Mauck WM; Hao Y; Stoeckius M; Smibert P; Satija R
    Cell; 2019 Jun; 177(7):1888-1902.e21. PubMed ID: 31178118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noncoding regions are the main source of targetable tumor-specific antigens.
    Laumont CM; Vincent K; Hesnard L; Audemard É; Bonneil É; Laverdure JP; Gendron P; Courcelles M; Hardy MP; Côté C; Durette C; St-Pierre C; Benhammadi M; Lanoix J; Vobecky S; Haddad E; Lemieux S; Thibault P; Perreault C
    Sci Transl Med; 2018 Dec; 10(470):. PubMed ID: 30518613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoepitope targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer.
    Meng Q; Valentini D; Rao M; Moro CF; Paraschoudi G; Jäger E; Dodoo E; Rangelova E; Del Chiaro M; Maeurer M
    Br J Cancer; 2019 Jan; 120(1):97-108. PubMed ID: 30377343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.
    Owens GL; Price MJ; Cheadle EJ; Hawkins RE; Gilham DE; Edmondson RJ
    Cancer Immunol Immunother; 2018 Oct; 67(10):1519-1531. PubMed ID: 30039427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.
    Jin BY; Campbell TE; Draper LM; Stevanović S; Weissbrich B; Yu Z; Restifo NP; Rosenberg SA; Trimble CL; Hinrichs CS
    JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1
    Donia M; Kjeldsen JW; Andersen R; Westergaard MCW; Bianchi V; Legut M; Attaf M; Szomolay B; Ott S; Dolton G; Lyngaa R; Hadrup SR; Sewell AK; Svane IM
    Clin Cancer Res; 2017 Oct; 23(19):5779-5788. PubMed ID: 28679768
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic T cell engineering.
    Sadelain M; Rivière I; Riddell S
    Nature; 2017 May; 545(7655):423-431. PubMed ID: 28541315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.
    Tran E; Robbins PF; Rosenberg SA
    Nat Immunol; 2017 Feb; 18(3):255-262. PubMed ID: 28198830
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.